Finerenone with empagliflozin beneficial for managing CKD and type 2 diabetes
1. Among patients with both chronic kidney disease (CKD) and type 2 diabetes (T2D) already on a renin-angiotensin system (RAS) inhibitor, a combination of finerenone and empagliflozin resulted in a greater reduction in the urine albumin-to-creatinine ratio (ACR) than either agent alone. 2. Safety profiles for both agents were consistent with existing clinical data, but […]
The post Finerenone with empagliflozin beneficial for managing CKD and type 2 diabetes first appeared on 2 Minute Medicine.Source: 2 Minute Medicine